The Research About the ACS After Femoropopliteal Arterial Injuries
Launched by HEBEI MEDICAL UNIVERSITY THIRD HOSPITAL · Aug 25, 2021
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called Acute Compartment Syndrome, which can occur after injuries to the femoropopliteal artery in the leg. This condition can happen when there’s not enough blood flow to the area for a long time, or if there are serious injuries to the surrounding tissues. The goal of the study is to understand better how to treat this condition, as there is currently some disagreement among doctors about the best approach.
To participate in this trial, individuals must be at least 18 years old and have suffered injuries to their femoropopliteal artery. Unfortunately, those who did not survive their hospital stay or who had their leg amputated will not be eligible. If someone qualifies, they can expect to be part of a study that seeks to improve treatment options for this serious condition. The trial is currently recruiting participants, and it welcomes individuals of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with femoropopliteal arterial injuries
- • patients older than 18 years
- Exclusion Criteria:
- • Patients who did not survive to discharge
- • Patients with primary amputation
- • patients younger than 18 years
About Hebei Medical University Third Hospital
Hebei Medical University Third Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices across various medical fields. With a commitment to ethical standards and patient safety, the institution collaborates with multidisciplinary teams to conduct rigorous clinical studies that contribute to the scientific community and enhance treatment options. Leveraging state-of-the-art facilities and a patient-centric approach, Hebei Medical University Third Hospital plays a vital role in the advancement of clinical research and the development of new healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shijiazhuang, Hebei, China
Patients applied
Trial Officials
Hou Zhiyong, Doctor
Principal Investigator
Hebei Medical University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials